Ambagon Therapeutics is an early-stage biotechnology company dedicated to the discovery and development of molecular glues stabilizing the interaction between the 14-3-3 adaptor proteins and their disease-promoting client proteins. Ambagon is located in Eindhoven, The Netherlands and we are a close-knit team that values communication, inclusion and respect.